Drug Type T-lymphocyte cell therapy |
Synonyms CTA-004 |
Target |
Action antagonists |
Mechanism HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Metastatic breast cancer | Preclinical | China | 01 Sep 2025 |





